HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

HER2/TOP2A Meta-analysis Study Group, Angelo Di Leo, Christine Desmedt, John M S Bartlett, Fanny Piette, Bent Ejlertsen, Kathleen I Pritchard, Denis Larsimont, Christopher Poole, Jorma Isola, Helena Earl, Henning Mouridsen, Frances P O'Malley, Fatima Cardoso, Minna Tanner, Alison Munro, Chris J Twelves, Christos Sotiriou, Lois Shepherd, David CameronMartine J Piccart, Marc Buyse

Research output: Contribution to journalArticlepeer-review

Abstract

Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast cancer.
Original languageEnglish
Pages (from-to)1134-42
Number of pages9
JournalThe Lancet Oncology
Volume12
Issue number12
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data'. Together they form a unique fingerprint.

Cite this